Grisham Rachel N, Hyman David M, Iyer Gopa
Memorial Sloan-Kettering Cancer Center, New York, New York.
Clin Adv Hematol Oncol. 2014 Mar;12(3):158-62.
Ovarian cancer remains the leading cause of death among women with gynecologic malignancies in the United States. Most women with epithelial ovarian cancer present with advanced disease. Despite good response rates to initial surgery and chemotherapy, the majority of patients experience relapse and ultimately die of their disease. A better understanding of the molecular differences underlying the histologic subtypes of epithelial ovarian cancer has led to recent advances in targeted therapeutic strategies. Here we review the most promising targeted therapeutics currently being used for the treatment of recurrent ovarian cancer.
在美国,卵巢癌仍然是妇科恶性肿瘤女性患者的主要死因。大多数上皮性卵巢癌女性患者就诊时已处于晚期。尽管初始手术和化疗的缓解率良好,但大多数患者会复发,最终死于该疾病。对上皮性卵巢癌组织学亚型潜在分子差异的更好理解,促成了靶向治疗策略的最新进展。在此,我们综述目前用于治疗复发性卵巢癌最有前景的靶向治疗方法。